NEW YORK, June 30 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced that the Company will present at the OneMedForum Emerging Company Finance Conference, hosted by OneMedPlace in New York City July 29 - 30, 2010.
Presentation Date: Wednesday, June 30, 2010
Time: 11:40 a.m. Eastern Time
Venue: The Roosevelt Hotel
New York City
"From our ground-breaking collaboration with the Vatican's Pontifical Council for Culture to the recent manufacturing expansion at our Suzhou Erye Pharmaceutical Subsidiary in China, as well as our important adult stem cell research and therapeutic development efforts, NeoStem has a truly compelling story to share with the investment community," said Robin Smith, M.D., NeoStem's CEO and Chairman of the board of directors. Dr. Smith continued, "Armed with a bolstered cash position, including a recent infusion of new capital from a small number of funds, we continue to pursue several attractive growth opportunities that we believe will meaningfully enhance shareholder value. We look forward to sharing our evolving story at this year's OneMedForum."
In addition to delivering her presentation at the conference, Dr. Smith will also be available for one-on-one meetings with prospective investors.
The goal of the "2010 New York OneMedForum" is to connect private and public (microcap) medtech, biotech and health information companies with a global group of active healthcare investors.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include the amount of additional capital the Company may require to pursue its growth opportunities and whether or not any of such growth opportunities will be realized, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.